ClinicalTrials.gg
Active, not recruitingNCT05205356Updated Jul 10, 2026

VIGOR: Virtual Genome Center for Infant Health

An observational study in Genetics Disease, Genetics/Birth Defects and Genetic Predisposition to Disease, sponsored by Boston Children's Hospital. Active, not recruiting at 10 sites in United States. Open to participants aged 0 Days to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Boston Children's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
631
Ages
0 Days to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 297 studies in Genetic Diseases, Inborn with a site in United States — 65 open to participants now, 100 under way, 15 of them phase 3. Genetic Diseases, Inborn · United States.

Enrollment
23rd of 111
631 · median 100
Started
2022
with 19 others
Observational
115 of 297
38 open now
Primary completion
2026-12
later than 23 of 93 live
Registered
223rd of 297
by date
Lead sponsor
6 of 297
Boston Children's Hospital

Among the 297 studies in Genetic Diseases, Inborn with a site in United States, this one is the 23rd largest by enrollment of the 111 observational ones that give a count, is one of 20 that started in 2022, is one of 115 observational ones, reaches primary completion later than 23 of the 93 other live ones, and was the 223rd registered.

Genetic Diseases, Inborn

585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

65 of the 297 studies in Genetic Diseases, Inborn with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 0 Days to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 297 studies in Genetic Diseases, Inborn with a site in United States, or all of them as a file.
02

Study summary

This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.

The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

Read the detailed description

Genomic medicine has rapidly advanced in the past decade enabling earlier diagnosis and personalized treatment. However, only a few highly specialized centers in the US have the resources to take advantage of these advances in patient care. This has created a large health equity gap whereby patients cared for in typical community settings, often low-income and/or representing racial/ethnic minorities, do not receive equitable medical care. Another barrier to the wider utilization of genomic medicine is the poor dissemination of knowledge among clinicians, especially in community settings. A wide gap exists in the implementation of genomic medicine from diagnosis to personalized therapies, a field experiencing huge advances but still subject to wide disparities in accessibility. This study aims to develop and test the implementation of a strategy to break down these barriers to genomic medicine. The target population is sick newborns admitted to the NICU that present with probable genetic conditions. This study proposes a novel center, VIrtual GenOme CenteR (VIGOR). VIGOR will be a center that can remotely support clinicians and families working in community NICUs.

This study will provide rigorous evaluation of implementing a virtual genome center at community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minorities (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.

The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

03

Conditions studied

  • Genetics Disease
  • Genetics/Birth Defects
  • Genetic Predisposition to Disease

Keywords

  • Genetics
04

Who can participate

Ages eligible
0 Days to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The VIGOR center will enroll and follow for 12 months 250 eligible newborns and their families within community NICUs in the US serving diverse populations. Among enrolled newborns, rapid genomic sequencing will be facilitated along with the creation and return of timely Clinical Interpretive Reports to families and providers. This study comprehensively examine implementation outcomes according to a well-established framework at the NICU, provider, and newborn/caregiver-level.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns presenting with probable genetic conditions inpatient on the NICU. These may include (but is not limited to) those with unexplained hypotonia, seizures, metabolic disorders, disorders of sex development, interstitial lung disease, immunodeficiency or multiple congenital anomalies.
  • Babies must have at least one biologic parent available for consent and participation.
  • The criteria for inclusion are 100% phenotype based and do not include any demographic parameters.

Exclusion criteria

Exclusion Criteria:

  • Presence of a likely nongenetic explanation for the phenotype (e.g., perinatal asphyxia explained by uterine rupture or placental pathology;
  • Clinical features pathognomonic for a recognizable chromosomal abnormality, such as trisomy 21;
  • Associations already known to have low genetic diagnostic yield, including VATER/VACTERL association and OEIS complex;
  • Infants who die before enrollment;
  • Known family history of genetic disease that is plausibly the cause of the infant's illness; - Those with a prenatal genetic diagnosis.
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
631 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Neonates and Parents/Caregivers

    Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child. We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history \& mental health; within 1 week of disclosure of findings to assess satisfaction \& mental health; \& at 3 \& 6 months to further assess mental health \& newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR \& receipt of GS results with their physician in more detail.

  • Clinicians

    Following focus groups at each of the participating sites to assess the feasibility \& needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation \& again between year 4 \& the completion of the study, to assess feasibility \& appropriateness of VIGOR. We will administer brief surveys to the care providers before \& after receipt of genomic education to assess their baseline knowledge \& comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process \& satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.

06

What researchers measure

Primary outcomes

  1. Implementation of VIGOR

    Penetration of VIGOR measured by percentage of eligible participants who were enrolled, tested, providers received CIR and completed a disclosure session.

    Time frame: 4 year

Secondary outcomes

  1. Implementation of VIGOR

    Appropriateness of VIGOR measured at the provider level by conducting focus groups/interviews.

    Time frame: 4 year

  2. Implementation of VIGOR

    Feasibility of VIGOR measured at the provider level by conducting focus groups/interviews.

    Time frame: 4 year

  3. Service Outcomes

    Equity in penetration of VIGOR use by race/ethnicity, insurance status and primary language measured at the participant level by conducting chart reviews and surveys.

    Time frame: 4 years

  4. Client Outcomes

    Function measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.

    Time frame: 4 years

  5. Client Outcomes

    Symptomatology measured at the infant/caregiver level by conducting surveys, and interviews.

    Time frame: 4 years

  6. Client Outcomes

    Satisfaction measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.

    Time frame: 4 years

07

Study locations

10 sites
08

References and documents

Publications

  • Hills S, Werner M, Douglas J, D'Gama AM, Wojcik MH, Young V; VIGOR Network; Yu TW, Agrawal PB, Parker MG. Understanding perspectives of safety-net NICU neonatologists disclosing genomic sequencing results: a mixed methods approach. J Perinatol. 2026 May 5. doi: 10.1038/s41372-026-02655-4. Online ahead of print. PubMed 42086727 ↗
  • D'Gama AM, Hills S, Douglas J, Young V, Genetti CA, Wojcik MH, Feldman HA, Yu TW, G Parker M, Agrawal PB; VIGOR Network. Implementation of rapid genomic sequencing in safety-net neonatal intensive care units: protocol for the VIrtual GenOme CenteR (VIGOR) proof-of-concept study. BMJ Open. 2024 Feb 6;14(2):e080529. doi: 10.1136/bmjopen-2023-080529. PubMed 38320840 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 94 non-industry observational studies under Genetic Diseases, Inborn, half reached primary completion within 124 months of starting (the median), counting those still running; a quarter within 46. This study's planned 57 months is below that.

Counting every sponsor, half of 128 studies reached it within 110 months; a quarter within 46 and three quarters within 193.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 25, 2022
StartActual
Mar 22, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 1, 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05205356
Collaborators
Boston Medical Center, Baystate Medical Center, UMass Memorial Health, The Cooper Health System, National Human Genome Research Institute (NHGRI), DHR Health Institute for Research and Development, The Hospitals of Providence East Campus, The Hospitals of Providence Memorial Campus, Jackson Health System, University of Texas, Driscoll Children's Hospital, University of South Alabama
Responsible party
Timothy Yu (Associate Professor of Pediatrics, Boston Children's Hospital) — Principal investigator
First posted
Jan 25, 2022
Start date
Mar 22, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Timothy Yu, MD, PhD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion